Overview

• In the 72-week ATTAIN-2 trial of more than 1,600 adults with obesity and type 2 diabetes, the 36 mg dose produced about 10.5% average weight loss versus roughly 2.2% with placebo.
• Patients on the highest dose saw A1C fall by up to 1.8 percentage points, with about 75% reaching 6.5% or below, a common diabetes threshold.
• Gastrointestinal side effects were the most common issues, including nausea (36.4%), vomiting (23.1%) and diarrhea (27.4%), with about 10.6% on the top dose discontinuing due to adverse events.
• Analysts note higher side‑effect‑related dropouts than seen in some injectable GLP‑1 studies, a factor that could influence real‑world use and coverage decisions.
• As a small‑molecule pill without fasting or water‑intake restrictions, orforglipron could be easier to manufacture and distribute, though Lilly trails Novo Nordisk, whose high‑dose oral Wegovy is already under FDA review.